No Data
On November 29, Corning Jereh Pharmaceuticals-B (09966) spent 2.2756 million Hong Kong dollars to repurchase 0.6 million shares.
Kangning Jerry Pharmaceuticals-B (09966) announced that on November 29, 2024, the company invested 227 million...
Hong Kong stocks unusual | Conic Jerry Pharmaceuticals-B (09966) fell nearly 4% as institutions lowered the peak sales of Envida and KN046 after adjustment of POS economics.
Corning Incorporated Pharma-B (09966) has dropped nearly 4%, as of this report, down 3.91%, trading at 3.91 Hong Kong dollars, with a turnover of 12.9509 million Hong Kong dollars.
【Brokerage Focus】Bocom Intl lowers the target price for Corning Pharmaceutical (09966) by 32.4% due to short-term pressure on product sales.
Jingu Finance News | Bocom Intl released research reports stating that Conagenix Pharmaceuticals (09966) is in the process of forming a HER2 pipeline matrix, with huge commercial value yet to be realized: 1) Phase I data of JSKN033 was first disclosed at the SITC conference and selected for LBA, showing a DCR of 80% in NSCLC patients with HER2 expression (IHC≥ 1+) or HER2 mutation. 2) Early clinical data of JSKN003 treating platinum-resistant ovarian cancer and HER2-positive (IHC 3+) solid tumors (excluding breast cancer) were presented at the ESMO conference, with ORRs reaching
Why Investors Shouldn't Be Surprised By Alphamab Oncology's (HKG:9966) 26% Share Price Surge
Alphamab Oncology Presents Clinical Study Results for Tumor Treatment at Houston Cancer Meet
Selected for LBA! The latest breakthrough clinical research results of Corning Jerry HER2 dual anti-ADC subcutaneous injection compound preparation JSKN033 will be presented at the 2024 SITC Annual Meeting.
On November 11, 2024 in Suzhou /PRNewswire/ -- Conic Jerry Biopharmaceutical (stock code: 9966.HK) announced that the first human clinical study results of the high-concentration subcutaneous injection compound preparation JSKN033 of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 inhibitor were selected for the latest breakthrough abstracts at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in 2024.
Alphamab Oncology's (HKG:9966) 31% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
No Data
